Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Publication

Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC

C. Le Tourneau, et al. SITC 2025 Abstract available on JITC website – Download the abstract – Download the Poster

Published 7 November 2025
Categorized as 2025, Myvac, Publication, publication key en, TG4050

Contribution of yeast to synthetic virology

C. Rey, et al. Virologie 2025 Read the article on the JLE website – Download the article

Published 25 October 2025
Categorized as -others, 2025, 2025, Myvac, Publication, Publication, publication key en, TG4050, TG6002

Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors

C. Lebbe, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster

Published 20 October 2025
Categorized as 2025, BT-001, Publication, publication key en

Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials

C. Ottensmeier, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster

Published 19 October 2025
Categorized as -others, 2025, Publication

TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma

J. Foloppe, et al. Frontiers in Microbiology Septembre 2025 – Download the Article

Published 24 September 2025
Categorized as -others, 2025, Publication, TG6002

A Pseudocowpox virus vector to generate human B cell-based vaccines

C. Thioudellet, et al. CICON 2025 – Download the Poster

Published 7 August 2025
Categorized as -others, 2025, Publication

Utilisation de l’analyseur xCELLigence RTCA eSight pour l’évaluation de la nouvelle plateforme de virus oncolytique de Transgene

B. Moreau et al.AFH 2025Download the poster herePoster presentation

Published 4 July 2025
Categorized as -others, 2025, Publication

Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)

C. Le Tourneau, et al. ASCO 2025 Abstract available on the ASCO website – Download the abstract – Download the Rapid Oral Presentation

Published 22 May 2025
Categorized as 2025, Myvac, Publication, publication key en, TG4050

A randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic(R/M) HPV16-positive cervical or anogenital cancer

C. Le Tourneau, et al. ASCO 2025 Abstract available on the ASCO website – Download the abstract – Download the Poster

Published 22 May 2025
Categorized as -others, 2025, Publication, TG4001, TG4001

A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer

E. J. West et al.Clinical Cancer Research April 2025Download the publication herePublication

Published 15 April 2025
Categorized as -others, 2025, Publication, TG6002

Posts pagination

Newer posts Page 1 Page 2 … Page 13 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu